NCT06516068Active, not recruitingPhase 2
A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
A Multicenter, Randomized, Open-label Phase II Clinical Study on the Efficacy and Safety of HRS-1893 in Obstructive Hypertrophic Cardiomyopathy Subjects.
Source: ClinicalTrials.gov · Last updated 16 Jul 2025
Brief summary (registry, in English)
The study is being conducted to evaluate the efficacy, and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- First submitted
- 28 Jun 2024
- Start date
- 11 Aug 2024
- Primary completion date
- 18 Nov 2024
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT06516068
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 42
- From 11 Aug 2024 to the primary completion date, 18 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of aortic stenosis or subaortic fixed stenosis;
Other illness
- Known or suspected invasive, genetic or storage diseases (e.g. Noonan syndrome, Fabre's disease, amyloidosis) that cause cardiac hypertrophy (similar to oHCM);
Lab values
- Previous left ventricular systolic dysfunction at any time in the clinical course (LVEF \< 45%);
Who the study is looking for
- Age 18-85 years old, gender unlimited;
- The diagnosis was obstructive hypertrophic cardiomyopathy.
- Echocardiographic laboratory tests showed LVEF≥60%;
- No previous left ventricular systolic dysfunction at any time (LVEF \< 45%);
- Understand the study procedure and sign the informed consent in person, willing to strictly follow the clinical study protocol to complete the study.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fuwai Hospital, Chinese Academy of Medical Sciences(CAMS) Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.